Skip Ribbon Commands
Skip to main content
Dr Zhou Zhi Dong

Dr Zhou Zhi Dong

Associate Clinician Scientist

Research (National Neuroscience Institute)

National Neuroscience Institute

Research Interest:
  • Molecular and therapeutic targets in neuron degeneration of Parkinson’s disease and other human neuron degenerative disorders
  • Therapeutic biomarker in Parkinson’s disease and other human neuron degenerative disorders

Research Appointments

  • Associate Clinician Scientist Research (National Neuroscience Institute) National Neuroscience Institute Research (National Neuroscience Institute)


Dr Zhou Zhi Dong graduated as a medical doctor in 1991 and had 5 years of postgraduate clinical training in internal medicine. Subsequently, Dr Zhou acquired his Ph.D from the Chinese Academy of Science in 2003, and his post-doctor training in research on Parkinson's Disease (PD) in DBS, NUS from 2003. Dr Zhou joined the National Neuroscience Institute (NNI) as a member of the National PD Translational Bench to Bedside team and continued to work on PD in NNI.

Currently, Dr Zhou is Associate Clinician Scientist at NNI and a regular rank Assistant Professor of NBD, Duke-NUS as well as a PI of NMRC grants. As a Clinician Scientist, Dr Zhou focuses on translational research on therapeutic targets in PD and other human neuron degenerative disorders. Dr Zhou is interested in searching and validating  new biomarkers in PD and other neuron degenerative diseases. His work will help uncover the molecular pathogenesis of PD and identify new therapeutic targets and biomarkers to improve diagnosis, prognosis and therapy of PD.

Professional Appointments and Committee Memberships

  • ​​Associate Clinician Scientist, Research, National Neuroscience Institute
  • Assistant Professor, Neuroscience and Behavioural Disorders Programme, Duke-NUS Medical School


  • ​Ph.D Chinese Academy of Science (China), 2003
  • Internal Medicine (China), 1996
  • MD (China), 1991


  • Khoo Bridge Funding Award, 2021
  • Long Service Award (10 years), 2019
  • NMRC Transition Award, 2013
  • Biotech Fair Award, 2011

Research Studies


  • ZD Zhou, SP Xie, WT Saw, PGH Ho, HY Wang, L Zhou, Y Zhao, EK Tan, The therapeutic implications of tea polyphenols against dopamine (DA) neuron degeneration in Parkinson’s disease (PD) Cells 8 (8), 911
  • Sarivin Vanan,, Xiaoxia Zeng, Sook Yoong Chia,, Zhi Dong Zhou, et al. Altered striatal dopamine levels in Parkinson’s disease VPS35 D620N mutant transgenic aged mice. Mol Brain, 13, Article number: 164 (2020) 2).
  • Zhi Dong Zhou & Eng King Tan. Oxidized nicotinamide adenine dinucleotide-dependent mitochondrial deacetylase sirtuin-3 as a potential therapeutic target of Parkinson’s Disease. Ageing Research Review. 2020. Sep;62:101107. doi: 10.1016/j.arr.2020.101107.
  • Zhi Dong Zhou, et al. Molecular targets for modulating the protein translation vital to proteostasis and neuron degeneration in Parkinson’s disease. Translational Neurodegeneration. 2019 in press.
  • Zhi Dong Zhou, Ji Chao Tristan Lee & Eng King Tan. Pathophysiological mechanisms linking F-box only protein 7 (FBXO7) and Parkinson’s disease (PD), Mutation Research/Reviews in Mutation Research 2018, 8: 72-78. ​
  • Zhi Dong Zhou at al. Dopamine (DA) toxicity in pathogenesis and therapy of Parkinson’s disease (PD). J Clin Bioanal Chem 2017;1(1):1-3.
  • Zhi Dong Zhou & Eng King Tan. Iron Regulatory Protein (IRP)-Iron Responsive Element (IRE) Signaling Pathway in Human Neurodegenerative Diseases. Molecular Neurodegeneration, 2017 12(1):75.
  • Zhong Can Zhen.,.Zhi Dong Zhou, et al. LRRK2 Interacts with ATM and Regulates Mdm2-p53 Cell Proliferation Axis in Response to Genotoxic Stress. Human Molecular Genetics. 2017, 26(22):4494-4505.
  • Bin Xiao, Xiao Deng, Grace Lim, Shaoping Xie, Zhi Dong Zhou, and et al. Superoxide drives progression of Parkin/PINK1-dependent mitophagy following translocation of Parkin to mitochondria. Cell death and Disease. 2017; 8(10):e3097.
  • Zhong Can Chen,,, Zhi Dong Zhou, et al. Phosphorylation of amyloid precursor protein by mutant LRRK2 promotes AICD activity and neurotoxicity in Parkinson’s disease. Science Signaling. 2017; 10(488).
  • Lifeng Qiu,, Z.D. Zhou, et al. Immature midbrain dopaminergic neurons derived from floor-plate method improve cell transplantation therapy efficacy for Parkinson’s disease. STEM CELLS Translational Medicine, 2017; 6(9):1803-1814.
  • Bin Xiao;, Z.D. Zhou; et al. p62-Mediated Mitochondrial Clustering Attenuates Apoptosis Induced by Mitochondrial Depolarization. BBA - Molecular Cell Research, 2017; 1864(7):1308-1317.
  • Murni T, Wen RJ, ,Z. D. Zhou, et al. Varied pathological and therapeutic response effects associated with CHCHD2 mutant and risk variants. Human mutation, 2017. (8):978-987.
  • Z.D. Zhou*, Chao YX, Tan EK. Potential Implications of Mitochondrial Unfolded Protein Response in the Pathogenesis and Therapy of Dopaminergic Neuron Degeneration in Parkinson’s Disease. JSM Biotechnol Bioeng 2017; 4: 1075.
  • Z.D. Zhou * et al. Dopamine (DA) Dependent Toxicity Relevant to DA Neuron Degeneration in Parkinson’s Disease (PD). Austin Journal Of Drug Abuse And Addiction. 2016; 3(1): 1010.
  • Yin Xia Chao,,  Zhi Dong Zhou, et al. Evaluation of Tenm4 association with essential tremor in Singapore Chinese population. Movement Disorders. 2016; 31, S100.
  • Z. D. Zhou* & Eng King Tan, Potential pathophysiological crosstalk between Parkin and FBXO7 signalling pathways. Electronical Journal of Biology. 2016. Vol. 12(4): 439-442.
  • Z. D. Zhou*, Wuan Ting Saw, Eng King Tan. Mitochondrial CHCHD containing proteins: physiologic functions and link with neurodegenerative diseases. Molecular Neurobiology, 2016 Sep 8. [Epub ahead of print], doi:10.1007/s12035-016-0099-5.
  • Yin Xia Chao, Z. D. Zhou, Eng-King Tan. Comment and response: Plasma Coenzyme Q10 Levels and Multiple System Atrophy. JAMA Neurology, 2016. 2016;73(12):1499.
  • Z. D. Zhou*, et al. Linking F-box protein 7 and Parkin to neuronal degeneration in Parkinson's disease (PD). Mol Brain, 2016; 9: 41.
  • Angeles, D C,, Zhou ZD, et al. Antioxidants inhibit Neuronal Toxicity in Parkinson’s Disease-linked LRRK2. Annals of Clinical and Translational Neurology, 2016; 3(4): 288–294,
  • Z. D. Zhou, et al. F-box protein 7 mutations promote protein aggregation in mitochondria and inhibit mitophagy. Hum Mol Genet. 2015;24(22):6314-30.
  • Chao YX, , Zhou ZD, ,et al. Association Analysis of COQ2 Variant in Dementia and Essential Tremor. Parkinson's Disorders. Volume 2015, Article ID 926280.
  • Angeles, D C,, Zhou ZD, et al. Thiol-peroxidases ameliorate LRRK2 mutant-induced mitochondrial and dopaminergic neuronal degeneration in Drosophila. Human Molecular Genetics 2014; 23:3157-65.
  • Z.D. Zhou, et al. Mutant PINK1 up-regulates tyrosine hydroxylase and dopamine levels leading to vulnerability of dopaminergic neurons. Free Radical Biology & Medicine, 2014. 68:220-33.
  • Z.D. Zhou, et al. “Ring finger protein 146 / iduna is a Poly(ADP-ribose) polymer binding and PARsylation dependent E3 ubiquitin ligase”. Cell Adhension & Migration. 2011. 5(6):463-71.
  • Z.D. Zhou, et al, LINGO-1 and neurodegeneration: pathophysiologic clues for essential tremor? Tremor and Other Hyperkinetic Movements (TOHM). 2012.
  • Z.D. Zhou, et al. “The Roles of Amyloid Precursor Protein (APP) in Neurogenesis, Implications to Pathogenesis and Therapy of Alzheimer's Disease (AD)”. Cell Adhension & Migration. 2011;5(4):280-92.
  • Z.D. Zhou, et al. “Iron species-mediated dopamine oxidation, proteasome inhibition, and dopaminergic cell demise: implications for iron-related dopaminergic neuron degeneration.” Free Radical Biology & Medicine, 2010;49(12):1856-71.
  • Z.D. Zhou & T.M. Lim, “Glutathione conjugates with dopamine-derived quinones to form reactive or non-reactive glutathione-conjugates, implications to dopaminergic neuron degeneration.” Neurochem Research, 2010; 35(11):1805-18.
  • Z.D. Zhou, et al. “Notch as a Molecular Switch in Neural Stem Cells (NSC),” IUBMB life, 2010; 62, 618-623.
  • Z.D. Zhou, et al. “Dopamine auto-oxidation aggravates non-apoptotic cell death induced by overexpression of human A53T mutant alpha-synuclein in dopaminergic PC12 cells”. Journal of Neurochemistry, 2009;108: 601-610.
  • Z.D. Zhou & T.M. Lim, “Role of glutathione (GSH) on dopamine (DA) oxidation, studied by improved tandem HPLC procedures plus ESI-MS.” Neurochem Research, 2009; 34: 316-326.
  • Z.D. Zhou, T.M. Lim, “Dopamine (DA) induced irreversible proteasome inhibition via DA derived quinones.” Free Radical Research, 2009; 43, 417-430.
  • Z.D. Zhou, et al. “Endogenous dopamine (DA) renders dopaminergic cells vulnerable to challenge of proteasome inhibitor MG132” Free Radical Research, 2008; 42: 456-466.
  • Z.D. Zhou, et al.  “Dopamine-related and caspase-independent apoptosis in dopaminergic neurons induced by overexpression of human wild type or mutant α-synuclein,” Experimental Cell Research, 2006; 312: 156-170.